| Suzanne Tollerud Ildstad | |
| Birth Name: | Suzanne Ildstad |
| Birth Date: | May 20, 1952 |
| Birth Place: | Hennepin County, Minnesota, US |
| Alma Mater: | Mayo Clinic Medical School |
| Occupation: | Physician, medical researcher |
| Known For: | Founding CEO of Talaris Therapeutics |
Suzanne Tollerud Ildstad (born May 20, 1952, in Hennepin County, Minnesota) is an American physician and medical researcher.[1] She is the Chief Scientific Officer and founding CEO of Talaris Therapeutics (her discovery of tolerogenic graft facilitating cells led to the formation of the company).[2] She also serves the board of directors. She is also the Jewish Hospital Distinguished Professor of Transplantation Research, Director of the Institute for Cellular Therapeutics,[3] Professor in the Department of Surgery with associate appointments in the Departments of Physiology & Biophysics and Microbiology & Immunology at the University of Louisville School of Medicine.[4]
After earning her medical degree at Mayo Clinic Medical School, Ildstad did her surgical residency at Massachusetts General Hospital, an immunology fellowship at the National Institutes of Health, and a pediatric surgery/transplant fellowship at Cincinnati Children's Hospital.
Ildstad was elected to the National Academy of Medicine in 1997 and in 2014 was made a fellow of the National Academy of Inventors.[5] [6]
Ildstad is a named inventor or co-inventor on more than 100 patents.
She changed her middle name to "Tollerud" upon her marriage to David J. Tollerud, M.D. They have a son and a daughter.[7]